Get ready for a crash course in glycoengineering as Thomas Rexer, CTO of eversyn, a spin-off of the Max Planck Institute Magdeburg, breaks down the significance of modifying glycans in biopharmaceuticals.Explore the science behind glycoengineering and its potential to enhance the properties of therapeutic proteins.Key Insights:Unlock new frontiers in glycoengineeringExplore the potential of glycoengineering to revolutionize biopharmaceuticalsEnsure seamless integration of glycoengineering into production processesDon't miss this episode as Thomas unveils the trends that will shape the future of glycoengineering, offering actionable insights for scientists, entrepreneurs, and biotech enthusiasts alike.Connect with Thomas Rexer:LinkedIn: https://www.linkedin.com/in/thomas-rexerWebsite: www.eversyn.de